Its 'possible' negotiations are taking place, can't discard that possibility.  Especially with the potential it has to seriously capture a good % of its market.

 

 But in the meantime, my point is, each ATM dilutes the target price doesn't it.

 

And agree, they also can't afford to run out of cash, or bringing the product to market will be a lot tougher to accomplish.    Just a tad disgusted that a target price of around $20-25 is now around $14-16/sh..    (and acknowledge that this is subject to 'change' once actual sales and margins and reimbursement numbers firm up)